You are here


Tyrosine Kinase Inhibitor (TKI), a molecular targeted therapy designed to block specific proteins that cause leukaemic cells to divide. Imatinib was the first generation in this class of oral therapy; dasatinib, nilotinib, bosutinib and ponatinib are second generation TKIs now used as 1st, 2nd, 3rd and 4th line therapy.

There is currently no content classified with this term.